Charles River Laboratories International, Inc. (CRL) — 分析摘要
Charles River Laboratories International, Inc.（CRL）的市值为14.15十亿美元，最近一年的营收同比增长了-0.9%。净利润率为-3.6%。当前市盈率为-59.3倍。
核心要点
- 营收同比变化-0.9%
- 净利润率-3.6%
- 市盈率-59.3倍
与SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH板块的其他公司相比，CRL的营收增长为-0.9%，市盈率为-59.3倍。
Charles River Laboratories International, Inc. (CRL)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 6.8x — 高杠杆，存在再融资风险
利息保障倍数为 0.8x — 盈利不足以覆盖利息支出
营业利润率 (2.3%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
净利润较上一期下降 65.2%。
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
行业
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
员工人数
19,700
总部
WILMINGTON, MA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。